Ulloa-Aguirre Alfredo, Zariñán Teresa
Research Support Network, National University of Mexico and National Institutes of Health, Mexico City, Mexico
Research Support Network, National University of Mexico and National Institutes of Health, Mexico City, Mexico.
Mol Pharmacol. 2016 Nov;90(5):596-608. doi: 10.1124/mol.116.104398. Epub 2016 Jul 5.
Follitropin, or follicle-stimulating hormone (FSH) receptor (FSHR), is a G protein-coupled receptor belonging to the glycoprotein hormone receptor family that plays an essential role in reproduction. Although its primary location is the gonad, the FSHR has also been reported in extragonadal tissues including bone, placenta, endometrium, liver, and blood vessels from a number of malignant tumors. The recently resolved crystal structure of FSH bound to the entire FSHR ectodomain has been instrumental in more clearly defining the role of this domain in ligand binding and receptor activation. Biochemical, biophysical, and structural data also indicate that the FSHR exists as a higher order structure and that it may heterodimerize with its closely related receptor, the luteinizing hormone receptor; this association may have physiologic implications during ovarian follicle maturation given that both receptors may simultaneously coexist in the same cell. FSHR heterodimerization is unique to the ovary because in the testes, gonadotropin receptors are expressed in separate compartments. FSHR self-association appears to be required for receptor coupling to multiple effectors and adaptors, for the activation of multiple signaling pathways and the transduction of asymmetric signaling, and for negative and positive receptor cooperativity. It also provides a mechanism through which the glycosylation variants of FSH may exert distinct and differential effects at the target cell level. Given its importance in regulating activation of distinct signaling pathways, functional selectivity at the FSHR is briefly discussed, as well as the potential implications of this particular functional feature on the design of new pharmacological therapies in reproduction.
促卵泡激素,即卵泡刺激素(FSH)受体(FSHR),是一种属于糖蛋白激素受体家族的G蛋白偶联受体,在生殖过程中发挥着至关重要的作用。尽管其主要位于性腺,但FSHR也已在性腺外组织中被报道,包括来自多种恶性肿瘤的骨、胎盘、子宫内膜、肝脏和血管。最近解析的与整个FSHR胞外域结合的FSH晶体结构,有助于更清晰地界定该结构域在配体结合和受体激活中的作用。生化、生物物理和结构数据还表明,FSHR以高阶结构形式存在,并且可能与其密切相关的受体促黄体生成素受体异源二聚化;鉴于这两种受体可能同时共存于同一细胞中,这种关联在卵泡成熟过程中可能具有生理意义。FSHR异源二聚化是卵巢所特有的,因为在睾丸中,促性腺激素受体在不同的区域表达。FSHR的自缔合似乎是受体与多种效应器和衔接蛋白偶联、激活多种信号通路和转导不对称信号以及受体负性和正性协同作用所必需的。它还提供了一种机制,通过该机制FSH的糖基化变体可能在靶细胞水平发挥不同的作用。鉴于其在调节不同信号通路激活中的重要性,本文简要讨论了FSHR的功能选择性,以及这一特殊功能特征对生殖领域新药理学疗法设计的潜在影响。